- To be held at COEX in Seoul from July 10th to 12th, with participation from global pharmaceutical companies such as Samsung Bioepis, Lonza, and Merck.

▲   PCMO Booth Design Model

PCMO (Director: Min Cho, hereafter referred to as the Center) has announced its participation in BIOPLUS-INTERPHEX KOREA 2024 (BIX 2024), to be held from July 10th to 12th at COEX in Gangnam, Seoul.

At BIX 2024, PCMO will promote its core CDMO (Contract Development and Manufacturing Organization) services and showcase advanced technologies in vaccine and biopharmaceutical manufacturing. Particularly, the PCMO will unveil plans for the mRNA vaccine and biopharmaceutical manufacturing facility scheduled to operate from 2025, attracting global biotech industry attention.

Since its establishment, PCMO has been supporting domestic companies in their global ventures and promoting the vaccine industry. Located in the Hwasun Vaccine Industry Special Zone, the PCMO has successfully completed 100 projects. Besides CDMO services, it provides support to mRNA vaccine companies and offers tailored on-site training services with the backing of the Ministry of Trade, Industry, and Energy and Jeollanam-do Province.

At the PCMO booth, visitors can receive consultations on various CDMO services, including microbial-based manufacturing, process development, formulation research, and cell bank manufacturing, in capacities of 50L, 200L, and 1,000L. Additionally, the PCMO aims to contribute to the development of the domestic bio industry through networking with industry stakeholders.

▲   PCMO Booth Location Guide

BIX 2024, co-hosted by the Korea Biotechnology Industry Organization and Reed Exhibitions Korea (RX Korea), will feature participation from 250 companies across 15 countries. The event will showcase diverse fields, including manufacturing and facilities, biotechnology, laboratory equipment and analysis, raw materials (pharmaceuticals, food, cosmetics), cold chain logistics and packaging, services (clinical, preclinical, consulting), digital healthcare, and hospitals, universities, and public institutions. 

Key side events include company presentations on the Open Innovation Stage, partnering matches, a startup awards ceremony, and a global IR session with domestic and international venture capitalists (VCs). These activities are designed to provide opportunities for Korean bio companies to enter overseas markets and offer insights for building a global network.